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ABSTRACT
Objectives Several clinical studies have suggested the 
adipocytokine adiponectin is involved in the progression 
of rheumatoid arthritis (RA). From this point of view, 
adiponectin might present a new therapeutic target. 
However, as adiponectin also exerts benefi cial effects 
in the human organism, a strategy that would allow its 
detrimental effects to be abolished while maintaining the 
positive effects would be highly favourable. To elucidate 
such a strategy, the authors analysed whether the 
different adiponectin isoforms induce diverging effects, 
especially with regard to rheumatoid arthritis synovial 
fi broblasts (RASF), a central cell type in RA pathogenesis 
capable of invading into and destroying cartilage.
Methods Affymetrix microarrays were used to screen 
for changes in gene expression of RASF. Messenger RNA 
levels were quantifi ed by real-time PCR, protein levels 
by immunoassay. The migration of RASF and primary 
human lymphocytes was analysed using a two-chamber 
migration assay.
Results In RASF, the individual adiponectin isoforms 
induced numerous genes/proteins relevant in RA 
pathogenesis to clearly different extents. In general, 
the most potent isoforms were the high molecular 
weight/middle molecular weight isoforms and the 
globular isoform, while the least potent isoform was the 
adiponectin trimer. The chemokines secreted by RASF 
upon adiponectin stimulation resulted in an increased 
migration of RASF and lymphocytes.
Conclusion The results clearly suggest a pro-
infl ammatory and joint-destructive role of all adiponectin 
isoforms in RA pathophysiology, indicating that in chronic 
infl ammatory joint diseases the detrimental effects 
outweigh the benefi cial effects of adiponectin.
With 1% prevalence worldwide, rheumatoid 
arthritis (RA) is a common form of arthritis that, 
although the onset of RA is more frequent later in 
life, can affect people at any age. Without adequate 
treatment, this severe chronic inﬂ ammatory joint 
disease inevitably causes loss of articular function 
and mobility. Even though effective therapeutics 
are now available against the progression of the dis-
ease, additional therapeutic options are still needed 
when current therapies fail or cause severe adverse 
effects. This is where the so-called adipocytokines 
may come into play.
The major source of adipocytokines is adipose 
tissue. It has now become evident that adipose 
tissue is not merely an immunologically inactive 
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type of connective tissue but also an important 
immunoendocrine organ producing hormones and 
cytokines.1–3 These factors have been collectively 
termed adipocytokines or, in short, adipokines. 
Adiponectin, leptin, resistin and visfatin are just 
a few examples of this growing number of highly 
bioactive substances with metabolic and immuno-
logical functions.4 5
Pathologically, adipokines appear to be involved 
in numerous chronic inﬂ ammatory diseases. This 
not only includes RA but also systemic lupus ery-
thematosus, ankylosing spondylitis and systemic 
sclerosis.6
Synovial hyperplasia accompanied by substan-
tial inﬂ ammation and degradation of joints7 is a 
key feature of RA, and rheumatoid arthritis syn-
ovial ﬁ broblasts (RASF) are a major player in these 
destructive processes.8–10 This RA-speciﬁ c cell type 
therefore presents a promising target for therapeu-
tic intervention. For that reason, we investigated 
the effects of the adipocytokine adiponectin on 
RASF in order to ﬁ nd out how this may affect the 
pathogenesis of RA.
Adiponectin, a C1q/tumour necrosis factor 
(TNF) homologue,11 lent itself to this question as 
its synovial ﬂ uid levels are signiﬁ cantly increased 
in RA patients compared with osteoarthritis 
patients as well as healthy controls,12 13 and hyper-
adiponectinemia is associated with an increased 
incidence of joint destruction14 or radiographic pro-
gression15 16 in RA patients. Of note, adiponectin 
is not only produced by adipose tissue but also by 
synovial ﬁ broblasts, endothelial cells, osteoblasts 
and cardiac myocytes.17–19 In a previous study,20
we were able to show that native adiponectin 
affects several RA effector cells.
Interestingly, adiponectin is not a homogenous 
entity but consists of several isoforms corre-
sponding to different oligomers with a ‘bouquet 
of ﬂ ower’ structure. Trimeric adiponectin, also 
called low molecular weight adiponectin, is com-
posed of three full-length adiponectin monomers 
forming a collagen triple helix with a C-terminal 
globular gC1q domain (head domain).21 Globular 
adiponectin consists of the head domain of tri-
meric adiponectin as a result of proteolytic cleav-
age.22–24 The adiponectin hexamer, the so-called 
middle molecular weight (MMW) adiponectin, is 
a combination of two trimeric adiponectin mol-
ecules, while an assembly of 12–18 monomers 
is collectively termed high molecular weight 
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(HMW) adiponectin.21 Even though some studies have inves-
tigated selected adiponectin isoforms,21 25–28 no studies have 
yet analysed the potentially differential effects of adiponec-
tin isoforms on effector cells involved in the pathophysiology 
of RA.
With adiponectin’s important functions in energy metabo-
lism and beneﬁ cial effects on the cardiovascular system,29 30 it 
might be unadvisable to modulate adiponectin levels systemi-
cally in order to prevent its disease-promoting effects in RA. 
Instead, inhibiting adiponectin locally at sites of joint destruc-
tion or targeting speciﬁ c isoforms could be viable options. 
Therefore, in this study we investigated whether adiponec-
tin isoforms differentially affect gene expression and protein 
secretion of RASF, and could thus provide targets for speciﬁ -
cally inhibiting the detrimental effects of adiponectin while 
preserving its beneﬁ cial effects. As rheumatoid synovium is 
strongly inﬁ ltrated by lymphocytes and migrating RASF, which 
can additionally invade the synovium and cartilage,8 we also 
analysed whether the factors induced by the different adi-
ponectin isoforms in RASF have chemoattractive properties on 
RASF and lymphocytes.
MATERIALS AND METHODS
Cell culture
Human primary synovial ﬁ broblasts and primary lymphocytes 
were cultured as described in the supplementary material (avail-
able online only).
Isolation of synovial fi broblasts
Synovial tissue samples were obtained from synovial biopsy 
specimens from RA and osteoarthritis patients who were 
undergoing joint surgery. All specimens were obtained with 
the approval of the Ethics Committee of the Justus-Liebig-
University of Giessen. All patients gave informed consent and 
fulﬁ lled the criteria of the American College of Rheumatology.31 
32 Following enzymatic digestion,33 34 primary synovial ﬁ bro-
blasts were isolated and cultured in supplemented Dulbecco’s 
modiﬁ ed Eagle’s medium as described previously.20
Isolation of lymphocytes from human whole blood
Lymphocytes were isolated by Ficoll-based density gradient 
centrifugation as described in more detail in the supplementary 
material (available online only).
Table 1 Affymetrix microarray results: differential gene induction in RASF by adiponectin isoforms
Gene name Gene symbol
Fold change 
native Ad
Fold change Ad 
HMW/MMW
Fold change 
Ad trimer Fold change gAd
Chemokines
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 4.8 4.7 3.4 5.8
Chemokine (C-C motif) ligand 5 (CCL5) RANTES 24.0 24.7 3.8 73.2
Chemokine (C-C motif) ligand 7 (CCL7) MCP-3 101.3 74.9 28.0 254.0
Chemokine (C-C motif) ligand 8 (CCL8) MCP-2 25.8 11.2 3.5 297.3
Chemokine (C-C motif) ligand 20 (CCL20) MIP-3α 1424.0 1547.0 82.9 728.3
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α 29.4 33.3 17.7 32.8
Chemokine (C-X-C motif) ligand 2 (CXCL2) GRO-β 33.5 43.9 12.6 19.7
Chemokine (C-X-C motif) ligand 3 (CXCL3) GRO-γ 99.6 234.0 34.6 60.2
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 37.8 121.7 9.1 12.6
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 5.5 5.6 3.7 4.1
Chemokine (C-X-C motif) ligand 8 (CXCL8) IL-8 43.4 50.5 28.2 47.6
Chemokine (C-X-C motif) ligand 9 (CXCL9) MIG 9.3 36.7 −3.1 48.9
Chemokine (C-X-C motif) ligand 10 (CXCL10) IP-10 161.0 78.6 2.1 1225.0
Chemokine (C-X-C motif) ligand 11 (CXCL11) I-TAC 130.9 88.0 −4.4 728.3
Cytokines
Interleukin 6 IL-6 6.4 6.5 6.6 8.9
Interleukin 11 IL-11 24.3 441.0 157.4 2.3
Other infl ammatory molecules      
Prostaglandin E synthase PTGES 3.4 4.6 2.4 9.4
Prostaglandin endoperoxide synthase 
2/cyclooxygenase 2
PTGS2/COX2 19.9 17.9 7.1 26.1
Pre-B cell growth and B cell activation
Bone marrow stromal cell antigen 2 BST2 200.8 100.4 28.0 1091.0
Receptors
Interleukin 7 receptor IL-7R 5.6 6.9 3.0 8.9
Interleukin 17 receptor B IL-17RB 2.6 2.1 1.0 2.8
Proteinases and peptidases
Matrix metallopeptidase 1 (interstitial collagenase) MMP1 11.6 13.6 5.2 12.4
Matrix metallopeptidase 3 (stromelysin 1 
progelatinase)
MMP3 62.5 115.6 36.3 16.2
Matrix metallopeptidase 10 (stromelysin 2) MMP10 88.7 599.9 94.4 17.0
Matrix metallopeptidase 12 (macrophage elastase) MMP12 49.9 222.7 10.1 12.6
Bone metabolism
Stanniocalcin 1 STC1 19.8 23.4 14.5 24.6
Growth factors
Fibroblast growth factor 10 FGF10 5.0 5.6 1.0 3.9
RASF (n=1) were treated with adiponectin isoforms or left untreated (control). Affymetrix microarray analysis (GeneChip HG U133A) was performed as described. 
The results indicate that genes from several functional groups are differentially regulated in RASF by adiponectin isoforms. The cut-off value for fold changes was 
≤2 (repression) or ≥2 (induction), respectively. Strongly repressed genes were low in number and of no known or well-defi ned function.
Ad, adiponectin; gAd, globular adiponectin; HMW, high molecular weight; MMW, middle molecular weight; RASF, rheumatoid arthritis synovial fi broblasts.
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Stimulation of RASF and OASF
RASF and osteoarthritis synovial ﬁ broblasts (OASF) from pas-
sages 3–8 were grown to 70–80% conﬂ uency and stimulated 
with 25 μg/ml of different human adiponectin forms (BioVendor, 
Heidelberg, Germany) for 15 h: native adiponectin (a mixture of 
different adiponectin  isoforms; recombinantly produced in HEK 
293 cells); HMW/MMW-enriched adiponectin (recombinantly 
produced in HEK 293 cells); trimeric adiponectin (recombinantly 
produced in HEK 293 cells; prevented from further oligomerisa-
tion by a single amino acid mutation) and globular adiponectin 
(recombinantly produced in Eschericia coli). Sodium dodecylsul-
phate polyacrylamide gel electrophoresis analysis images of the 
commercially available adiponectin preparations, which were 
used, are shown in supplementary ﬁ gure S1 (available online 
only). The stimulation time was chosen based on preliminary 
experiments that demonstrated optimal response after 15 h.18
Unstimulated RASF and OASF were used as negative controls. 
Dose-response analyses were performed previously18 and 
showed that the induction of interleukin (IL)-6 and pro-matrix 
metalloproteinase (MMP) 1 by adiponectin does not reach a 
plateau until a concentration of approximately 100 μg/ml. We 
additionally showed that potential lipopolysaccharide contami-
nations of recombinant adiponectin were not responsible for the 
effects observed after stimulation.20
Affymetrix gene chips
RASF (passage 5; n=1) were stimulated for 15 h with 25 μg/ml of 
the different adiponectin isoforms as described above. Affymetrix 
(Santa Clara, CA, USA) microarray analysis was performed as 
described in the supplementary material (available online only).
Real-time PCR
Reverse transcription of RNA and real-time PCR were performed 
as described in the supplementary material (available online only).
Immunoassays
The cytokine, chemokine, MMP and adiponectin levels in cell 
culture supernatants were measured using commercially avail-
able ELISA (R&D Systems, Wiesbaden, Germany). 
Two-chamber migration assay
Media from adiponectin-stimulated RASF were analysed for 
their chemoattractive potential on RASF and lymphocytes using 
a two-chamber migration system. The procedure is described in 
detail in the supplementary material (available online only).
Statistical analysis
Biological or experimental replicates were used to calculate 
arithmetic means and standard errors of the mean (SEM). Data 
are presented as the mean±SEM. In order to assess the sig-
niﬁ cance of differences, a Student’s two-tailed t test was per-
formed for pairwise comparisons. For multiple comparisons, 
analysis of variance including Tukey’s post-hoc test was per-
formed. p Values less than 0.05 were considered signiﬁ cant. 
Statistical calculations were performed using Microsoft Excel 
and GraphPad Prism.
RESULTS
Differential induction of chemokines in RASF 
by adiponectin isoforms
RASF are an RA-speciﬁ c cell type capable of driving inﬂ amma-
tion and joint destruction,9 of invading into cartilage,35 and of 
migrating from joint to joint.8 Inhibiting their destructive activ-
ity is a desirable goal in RA therapy. Factors that promote or 
inhibit this activity are thus of substantial interest as potential 
therapeutic targets. We therefore analysed the effects of the dif-
ferent adiponectin isoforms on RASF gene expression, focusing 
on ﬁ nding out whether there are differences in the effects of the 
adiponectin isoforms and to what degree each isoform might be 
involved in RA pathogenesis.
Figure 1 (A) Differential induction of chemokine mRNA expression 
in rheumatoid arthritis synovial fi broblasts (RASF) by adiponectin (Ad) 
isoforms (real-time PCR data). Multiple RASF populations (n=4) were 
stimulated with adiponectin isoforms or left unstimulated (control). X-fold 
changes in mRNA expression of several chemokines were determined 
by real-time PCR and are shown (as arithmetic mean) in comparison for 
all adiponectin isoforms used for stimulation. (B) Differential induction 
of cytokine, chemokine and matrix metalloproteinase (MMP) secretion 
by RASF upon stimulation with adiponectin isoforms. Multiple RASF 
populations (n=4–15, see table 3) were stimulated with adiponectin 
isoforms or left unstimulated (control). X-fold changes in protein 
secretion of cytokines, chemokines and MMP were determined by 
ELISA and are shown (as arithmetic mean) in comparison for all 
adiponectin isoforms used for stimulation. HMW, high molecular weight; 
MMW, middle molecular weight.
annrheumdis-2011-200924.indd   3 8/23/2012   3:39:58 AM
1726 Ann Rheum Dis 2012;71:1724–1732. doi:10.1136/annrheumdis-2011-200924
group.bmj.com on September 5, 2017 - Published by http://ard.bmj.com/Downloaded from 
Basic and translational research
First, Affymetrix microarray analysis (GeneChip HG U133A) 
was performed in order to compare the gene expression of RASF 
stimulated with the different adiponectin isoforms or RASF left 
unstimulated. As large amounts of messenger RNA are required 
for Affymetrix microarrays and patient material was limited, 
one RASF population (n=1) was analysed exemplarily in this 
experiment to screen for changes in gene expression. The vari-
ability of different RASF populations was later accounted for by 
verifying selected results with higher n numbers. Chemokines 
were the largest group of dysregulated genes and were differen-
tially induced by the adiponectin isoforms (table 1). Veriﬁ cation 
of selected chemokines (GRO-α/-β/-γ, ENA-78, GCP-2, MCP-1, 
MCP-3) by real-time PCR conﬁ rmed the differential induction 
of mRNA expression in multiple RASF populations (table 2 and 
ﬁ gure 1A). Using immunoassays, we conﬁ rmed that chemokine 
secretion (GRO-α, ENA-78, GCP-2, IL-8, MCP-1, RANTES) 
was also differentially regulated by the individual adiponectin 
isoforms (table 3 and ﬁ gure 1B). I-TAC (CXCL11) and MIP-3α 
(CCL20) protein, however, could not be detected in either cell 
culture supernatants or cell lysates (data not shown). In particu-
lar, within the real-time PCR and immunoassay results, we could 
identify a distinct pattern regarding the effect of the different 
adiponectin isoforms on RASF; overall, HMW/MMW-enriched 
and globular adiponectin were the most potent isoforms, while 
the adiponectin trimer was the least effective. Native adiponec-
tin, which has not been enriched for any isoform, mostly held a 
middle ground but was rather variable in its potency depending 
on the regulated gene or protein. These observations are illus-
trated in ﬁ gure 1.
Differential induction of cytokines, MMP and other RA-related 
genes in RASF by adiponectin isoforms
Not only chemokines, but also pro-inﬂ ammatory cytokines, 
MMP and inﬂ ammation-related enzymes play a major role in 
RA pathogenesis. Their regulation is therefore crucial.
Our results showed that cytokines, MMP and other RA-related 
molecules were also regulated to very different extents depending 
on the particular adiponectin isoform (tables 1 and 3, ﬁ gure 1B). For 
example, secretion of the pro-inﬂ ammatory cytokine IL-6 was most 
strongly induced by HMW/MMW-enriched adiponectin, while the 
weakest response was seen with trimeric adiponectin. Similar dif-
ferential inductions by the individual adiponectin isoforms could 
be observed for the inﬂ ammation-related enzyme cyclooxygenase 
2 (COX2) as well as the MMP 1, 3, 10 and 12.
Biological variability of RASF cell populations in response to 
adiponectin stimulation
Different RASF cell populations, ie, synovial ﬁ broblasts obtained 
from different RA patients, showed highly variable responses 
to stimulation with adiponectin. Adiponectin upregulated gene 
expression or protein secretion in all cell populations that 
were analysed but to very different extents, which is illustrated 
in ﬁ gure 2A.
Response of OASF to adiponectin stimulation 
in comparison with RASF
Synovial ﬁ broblasts from RA patients and osteoarthritis patients 
responded similarly to stimulation with adiponectin isoforms, 
but OASF generally showed a weaker mean response than RASF, 
Table 2 Differentially induced chemokine mRNA expression in RASF by adiponectin isoforms
Gene name Symbol Ad Isoform Fold change SEM n p Value
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α Native 23.9 8.9 4 0.036
HMW/MMW 148.0 85.4 4 0.009
Trimer 14.1 8.1 4 0.021
Globular 206.8 134.9 4 0.009
Chemokine (C-X-C motif) ligand 1 (CXCL2) GRO-β Native 23.3 8.0 4 0.054
HMW/MMW 106.2 57.5 4 0.008
Trimer 9.3 4.5 4 0.021
Globular 121.1 68.8 4 0.008
Chemokine (C-X-C motif) ligand 1 (CXCL3) GRO-γ Native 66.3 50.8 4 0.020
HMW/MMW 77.7 36.7 4 0.005
Trimer 4.9 1.9 4 0.072
Globular 33.3 13.4 4 0.008
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 Native 70.8 41.9 4 0.006
HMW/MMW 57.7 24.7 4 0.002
Trimer 3.8 0.6 4 0.002
Globular 22.2 8.4 4 0.054
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 Native 112.0 45.7 4 0.019
HMW/MMW 584.6 327.7 4 0.003
Trimer 22.3 14.8 4 0.025
Globular 410.2 233.7 4 0.003
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 Native 7.2 1.9 4 0.008
HMW/MMW 11.9 3.0 4 0.005
Trimer 2.7 0.5 4 0.013
Globular 57.9 20.2 4 0.005
Chemokine (C-C motif) ligand 7 (CCL7) MCP-3 Native 16.3 9.1 4 0.015
  
HMW/MMW 17.8 7.9 4 0.007
Trimer 3.9 2.4 4 0.151
Globular 56.1 38.1 4 0.077
Multiple populations of RASF (n=4) were stimulated with different adiponectin isoforms. RNA was isolated, reverse transcribed to complementary DNA and quantifi ed by real-time 
PCR. Fold changes in mRNA expression (as compared to an unstimulated control), biological variability indicated by the (SEM), number of populations analysed (n), and the p values 
are presented.
Ad, adiponectin; HMW, high molecular weight; MMW, middle molecular weight; RASF, rheumatoid arthritis synovial fi broblasts.
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Table 3 Differentially induced cytokine, chemokine and MMP secretion in RASF by adiponectin isoforms
Protein name Symbol Ad isoform Fold change SEM n p Value
Chemokines
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α Native 125.1 43.0 9 0.024
 HMW/MMW 150.9 44.8 5 0.023
Trimer 19.0 12.5 5 0.223
Globular 75.8 26.4 5 0.027
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 Native 22.5 6.2 13 0.005
HMW/MMW 29.5 5.4 8 0.001
Trimer 9.9 3.9 8 0.056
Globular 14.8 5.2 8 0.033
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 Native 58.5 23.1 15 0.026
HMW/MMW 164.1 36.4 14 0.001
Trimer 22.8 6.1 14 0.003
Globular 110.3 35.8 14 0.009
Chemokine (C-X-C motif) ligand 8 (CXCL8) IL-8 Native 611.3 193.2 14 0.008
HMW/MMW 953.2 275.0 14 0.004
Trimer 135.6 50.8 14 0.020
Globular 570.5 223.1 14 0.024
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 Native 15.8 3.6 13 0.001
HMW/MMW 23.0 4.15 8 0.001
Trimer 17.2 7.9 8 0.081
Globular 18.5 6.9 8 0.040
Chemokine (C-C motif) ligand 5 (CCL5) RANTES Native 44.4 25.1 8 0.127
HMW/MMW 77.5 17.8 8 0.004
Trimer 10.0 7.8 8 0.381
Globular 145.3 35.6 8 0.005
Cytokines
Activin A INHBA Native 15.1 6.0 9 0.047
HMW/MMW 32.0 9.8 4 0.099
Trimer 7.3 2.2 4 0.065
Globular 2.8 1.2 4 0.212
Interleukin 6 IL-6 Native 31.2 9.7 12 0.010
HMW/MMW 57.0 16.9 12 0.007
Trimer 20.7 7.1 12 0.019
Globular 26.8 9.9 12 0.024
Proteinases & Peptidases
Matrix metallopeptidase 1, propeptide pro-MMP1 Native 11.9 8.1 13 0.206
HMW/MMW 24.4 15.9 13 0.014
Trimer 8.2 5.1 13 0.185
Globular 6.5 1.8 13 0.028
Matrix metallopeptidase 3 MMP3 Native 10.3 3.5 10 0.025
HMW/MMW 19.2 4.1 8 0.001
Trimer 4.3 1.5 8 0.063
Globular 12.6 3.8 8 0.014
Matrix metallopeptidase 10 MMP10 Native 4.4 1.1 11 0.009
 
HMW/MMW 11.6 2.1 11 0.002
Trimer 2.7 0.5 11 0.006
Globular 4.7 1.5 11 0.043
Multiple populations of RASF (n=4–15) were stimulated with different adiponectin isoforms. Secreted chemokines, cytokines and matrix metalloproteinases were quantifi ed by 
immunoassays. Fold changes of secretion (as compared to an unstimulated control), biological variability indicated by the (SEM), number of populations analysed (n), and the 
p values are presented.
Ad, adiponectin; HMW, high molecular weight; MMP, matrix metalloproteinases; MMW, middle molecular weight; RASF, rheumatoid arthritis synovial fi broblasts.
demonstrating the special phenotype of RASF (ﬁ gure 2B). However, 
due to the high biological variability of the cell populations, sta-
tistical signiﬁ cance for the differences between RASF and OASF 
responses could not be reached in most cases. Although the dif-
ferences in the response towards the different adiponectin iso-
forms were not as prominent as for RASF, differences could also 
be detected for OASF.
Chemoattractive effect of adiponectin-induced factors 
on RASF and lymphocytes
As outlined above, adiponectin isoforms induced numer-
ous chemokines. We therefore investigated to what extent 
this leads to a functional chemoattractive effect on RASF and 
lymphocytes, two key cell types in RA. A two-chamber migra-
tion assay was performed with RASF and primary human lym-
phocytes. Conditioned media from RASF cultures incubated 
with the different adiponectin isoforms were used as potential 
chemoattractants against medium from unstimulated RASF 
incubated in parallel. RASF were allowed to migrate for 15 h, 
lymphocytes for 4 h. Cells that actively passed the membrane of 
the two-chamber migration system were counted. The gradient-
free baseline was set to 100%.
Here, we observed an increased migration for RASF and 
lymphocytes towards conditioned medium from adiponectin-
stimulated RASF, indicating that the adiponectin-induced fac-
tors have a signiﬁ cant chemoattractive effect on RASF (n=3) 
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Figure 2 (A) Biological variability of rheumatoid arthritis synovial fi broblasts (RASF) cell populations in response to adiponectin (Ad) stimulation. 
Chemokine (ENA-78 and IL-8), cytokine (IL-6) and matrix metalloproteinase (MMP3) secretion was quantifi ed by ELISA after adiponectin stimulation 
of cultured RASF from different rheumatoid arthritis (RA) patients. To illustrate the biological variability of RASF populations in response to adiponectin 
stimulation, the individual results (x-fold changes in protein secretion) are shown as dots. The arithmetic mean is displayed as a bar. (B) Response of 
osteoarthritis synovial fi broblasts (OASF) to adiponectin stimulation in comparison with RASF. Multiple OASF populations (n=4 for GRO-α; n=12 for 
GCP-2; n=4 for RANTES; n=12 for MCP-1/native adiponectin and n=8 for MCP-1/other adiponectins) were stimulated with adiponectin isoforms in 
parallel with multiple RASF populations (see table 3 for n numbers). Chemokine secretion was quantifi ed by ELISA. Black bars indicate x-fold changes 
in protein secretion for RASF, while white bars indicate x-fold changes in protein secretion for OASF (each compared with unstimulated controls). Data 
are shown as the mean±SEM. HMW, high molecular weight; MMW, middle molecular weight.
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Figure 3 (A) Chemoattractive effect of adiponectin (Ad)-induced factors on rheumatoid arthritis synovial fi broblasts (RASF). Medium from 
RASF stimulated with different adiponectin isoforms was used in a two-chamber migration assay as a chemoattractant for RASF (n=3). The 
baseline (without chemotactic gradient) was set to 100%. Migration of RASF is expressed relative to the baseline. Using serum-free medium as 
a chemorepellent decreased RASF migration to 38%, while using 10% fetal calf serum medium as a positive control increased RASF migration by 
278% (data not shown). (B) Chemoattractive effect of adiponectin-induced factors on lymphocytes. Medium from RASF stimulated with different 
adiponectin isoforms was used in a two-chamber migration assay as a chemoattractant for lymphocyte (n=3) and analysed as described above. 
Using serum-free medium as a chemorepellent decreased lymphocyte migration to 35%, while using RANTES (10 ng/ml) plus SDF (Stromal Cell-
Derived Factor) (100 ng/ml) as a positive control increased lymphocyte migration by 345% (data not shown). Data are shown as the mean±SEM. 
*p<0.05; **p<0.01; ***p<0.001. HMW, high molecular weight; MMW, middle molecular weight.
(ﬁ gure 3A) and lymphocytes (n=3) (ﬁ gure 3B). Additional con-
trols with adiponectin (25 μg/ml) added just before the start of 
the migration assay showed that adiponectin itself does not 
have any chemoattractive properties on the cell types analysed 
(data not shown).
In summary, factors induced by adiponectin isoforms had 
a differential effect on RASF and lymphocyte migration, thus 
reﬂ ecting the individual effects of the respective adiponectin iso-
forms on protein secretion by RASF.
DISCUSSION
The primary objective of this study was to investigate if the dif-
ferent isoforms of the adipokine adiponectin have differential 
effects on RASF, a key cell type in RA pathogenesis. Previous 
data14–16 20 have suggested that adiponectin may be rather detri-
mental in RA and involved in disease progression. However, as 
available data have indicated that adiponectin is beneﬁ cial for 
metabolic and cardiovascular health,29 30 systemic elimination in 
order to avoid the harmful effects in RA might not be a favour-
able option. Based on initial data,27 28 researchers concluded 
that mainly HMW adiponectin is responsible for the vascular-
protective effects of adiponectin. On the other hand, available 
data have suggested that adiponectin promotes RA progres-
sion14–16 and does this most likely by inducing the secretion 
of pro-inﬂ ammatory molecules (eg, IL-6, COX-2), chemokines 
(eg, IL-8, MCP-1) and matrix-degrading enzymes (eg, MMP3).20
Adiponectin is thus able to mount and sustain a pro-inﬂ am-
matory response in various pathophysiologically relevant cell 
types in RA and osteoarthritis, including chondrocytes20 36 37
and RASF,20 both of which share the common characteristics of 
mesenchymal-derived cells.
These results led to the hypothesis that inhibition of speciﬁ c 
adiponectin isoforms might help circumvent the problem of 
reducing the harmful effects of adiponectin in RA while main-
taining its beneﬁ cial effects. However, our results showed that 
even though the individual adiponectin isoforms have differ-
ent potencies to modulate gene expression of RASF they do 
not have opposing effects or no effect at all in the setting of RA 
pathophysiology. Nonetheless, our results suggest that certain 
isoforms of adiponectin are more detrimental in RA than oth-
ers. Therefore, when considering adiponectin as a progression 
or activity marker for RA, it may be best to look at the most 
potent isoforms.
With regard to functional aspects of adiponectin isoforms, 
we were able to show that adiponectin-induced factors pro-
mote the migration of RASF and lymphocytes in vitro, which in 
vivo may lead to increased synovial lymphocyte inﬁ ltration and 
additional inﬂ ux of RASF to sites of inﬂ ammation and cartilage 
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degradation. Inhibition of these processes by blocking the local 
effects of speciﬁ c adiponectin isoforms within the joints could 
therefore lead to reduced disease progression and activity.
Another interesting observation was the high variability of 
RASF in response to adiponectin isoform stimulation, which 
may be attributed to different genetic proﬁ les38 39 as well as epi-
genetic variations between RASF populations.40 This is also in 
line with clinical ﬁ ndings showing that there are considerable 
differences in how RA patients respond to the different avail-
able medications. RASF possess a special phenotype reﬂ ected 
not only in their ability to migrate and invade into cartilage,8 
but also in their ability to respond to external stimuli such as 
adiponectin, which was illustrated here by the weaker response 
of OASF to adiponectin compared with RASF.
When considering strategies for modulating the effects of 
adiponectin, there are other conceivable options besides modu-
lating adiponectin itself: targeting adiponectin receptors41–43 
or co-receptors,44–47 and inhibiting the oligomerisation of adi-
ponectin isoforms by small molecule inhibitors that prevent the 
assembly into higher molecular weight isoforms.
With respect to animal models, the viability of adiponectin 
knock-out mice indicates that, at least in mice, adiponectin is 
not vital, but results regarding the effects of adiponectin knock-
out or overexpression in vivo are controversial. While Shinoda 
et al48 found no abnormalities regarding bone mass and turnover 
in Ad-/Ad- mice, Williams et al49 as well as Oshima et al 50 found 
an increased bone density. Conversely, adiponectin overexpress-
ing mice had increased bone mass, parameters of bone resorp-
tion and bone erosion were not affected.51 Contrary to what we 
would have expected based on our results, adenovirus-mediated 
systemic expression of human adiponectin in collagen-induced 
arthritis mice reduced clinical disease activity scores of collagen-
induced arthritis.52 Most likely, this result reﬂ ects the distinct 
phenotype of human RASF and the difference between human 
and murine arthritides.
Several groups also analysed the overexpression or knockdown 
of adiponectin in mouse models in the metabolic and vascular 
context.53–57 Under special nutritional conditions (high-fat and/or 
high-glucose diet) or on an obesity background (ob/ob), antidia-
betic and anti-atherogenic properties were observed for the over-
expression of adiponectin, while adiponectin knockout resulted 
in insulin resistance and impaired glucose metabolism. Therefore, 
it is always important to consider the experimental environment 
when looking at the in-vivo effects of adiponectin.
Also, as yet nothing is known about the role of adiponectin 
isoforms in mice, their occurrence and distribution. It therefore 
remains questionable to what extent the existing adiponectin 
knock-out mouse models are able to provide hints on how adi-
ponectin isoform deprivation would affect human RA.
In conclusion, while adiponectin may present an interesting 
therapeutic target in RA, more research is required to elucidate 
whether adiponectin isoforms can be targeted speciﬁ cally and 
respective inhibitors can be used to provide new therapeutic 
approaches. Nonetheless, the clearly different potencies of adi-
ponectin isoforms in RA suggest that considering the isoforms 
may be of value when utilising adiponectin as a marker for risk, 
activity or progression of RA.
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